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Background: Accumulating evidence showed that microRNAs are involved in development and progression of
multiple tumors. Recent studies have found that miR-181a were dysregulated in several types of cancers, however,
the function of miR-181a in hepatocellular carcinoma (HCC) remains unclear. In this study we assessed the potential
association between miR-181a, HBV and HCC.
Methods: The expression of miR-181a in HBV-expressing cells was determined by using qRT-PCR. Dual-Luciferase
reporter Assay, qRT-PCR and western blot were performed to investigate the target genes of miR-181a. The effects
of miR-181a on HCC proliferation were analyzed by MTS and colony formation assay. Tumor growth assay was used
to analyze the effect of miR-181a on tumor formation.
Results: HBV up-regulated miR-181a expression by enhancing its promoter activity. Overexpression of miR-181a in
hepatoma cells promoted cell growth in vitro and tumor formation in vivo. Conversely, inhibition of miR-181a
suppressed the proliferation of HBV-expressing cells. Mechanism investigation revealed that miR-181a inhibited the
expression of transcription factor E2F5 by specifically targeting its mRNA 3′UTR. Moreover, E2F5 inhibition induced
cell growth and rescued the suppressive effect of miR-181a inhibitor on the proliferation of SMMC-7721 cells.
Interestingly, we also discovered that HBV could down-regulate E2F5 expression.
Conclusions: Those results strongly suggested that HBV down-regulated E2F5 expression, in part, by up-regulating
the expression of miR-181a. Up-regulation of miR-181a by HBV in hepatoma cells may contribute to the progression
of HCC possibly by targeting E2F5, suggesting miR-181a plays important role in HCC development.
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Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths around the world. There
are about 21,000 new cases diagnosed each year and
700,000 people died due to HCC annually [1,2]. Chronic
hepatitis B virus (HBV) infection is the most prominent
cause for HCC, which accounts for 55% of cases world-
wide and 80% or more of those in the eastern Pacific* Correspondence: tanghua86162003@aliyun.com
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stated.region and sub-Saharan Africa [3-5]. However, the mech-
anism by which HBV contributes to the development of
HCC remains unclear. Thus, a better understanding of the
molecular mechanisms underlying HBV-related HCC will
be critical for the improvement of therapeutic strategies
for HCC patients.
MicroRNAs (miRNAs) are a novel class of small non-
coding RNAs, which play important roles in many of
the major biological processes in eukaryotic cells by
regulating their target genes post-transcriptionally [6].
Their target genes include numerous regulators of bio-
logical processes, such as cell differentiation, proliferation,
apoptosis, metabolism, development, and immunity [7,8].
Therefore, miRNAs are implicated in multiple biological. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tumorigenesis and cancer progression [9].
MicroRNA-181a (miR-181a) is a multifunction miRNA
that participates in many biological processes such as
apoptosis, cell proliferation and cellular invasion [10,11].
In recent years, the miR-181 family was found dysregu-
lated in a variety of human cancers and significantly as-
sociated with clinical outcome of cancerous patients [8].
It has been reported that miR-181a significantly overex-
pressed in a wide variety of cancers, such as gastric cancer
[11] and oral squamous cell carcinoma [12]. However, the
expression and role of miR-181a in HCC has not yet
been characterized. A study of miRNA microarray by
our laboratory has shown that miR-181a was signifi-
cantly increased in HBV-expressing HepG2.2.15 cells
compared with HepG2 [13]. This study attempted to
evaluate the mechanism of the increasing of miR-181a
in HepG2.2.15 as well as the influence of miR-181a
overexpression on HCC.
In the present study, we investigated the potential asso-
ciation between miR-181a, HBV and HCC. We examined
the expression levels of miR-181a in HCC cell lines and
investigate its effect on cell growth. In addition, we also
examined the potential role of miR-181a on HCC
tumorigenesis in a murine model. Finally, we explored
the underlying mechanism of miR-181a functions in
HCC. Our study will provide a new perspective in un-
derstanding the mechanism of HBV contributing to
HCC development.
Methods
Cell lines and transfection
The HCC cell lines, HepG2 and SMMC-7721 (Both cell
lines are HBV negative) were obtained from the American
Type Culture Collection and HepG2.2.15 (HBV positive)
was purchased from the Shanghai Second Military Med-
ical University. HepG2 and HepG2.2.15 cell lines were
cultured in MEM (Hyclone, China) with 10% FBS
(Gibco, USA), 100U/ml penicillin and streptomycin,
5 mmol/L glutamine. SMMC-7721 was cultured in RPMI-
1640 (Hyclone, China) supplemented with 100U/ml peni-
cillin and streptomycin. Cells were maintained in a
humidified 37°C incubator with an atmosphere of 5%
CO2. Transfections were performed with a Lipofectamine
2000 kit (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s instructions. Transfected cells were harvested
at 48 hours.
Construction of vectors
The miR-181a promoter construct pGL3-miR-181a-P
was generated from HepG2 cell genomic DNA. The
primers used to amplify the sequence (-800 ~+240) were 5′-
ACGGTACCTGCAGGATCTCAGCAAAGGA-3′ (forward)
and 5′- ACCTCGAGAGGAACAGTGAGCAGTAGGA-3′(reverse). pTARGET-miR-181a vector, which can stable
express of miR-181a, contains pri-miR-181a and some of
its flanking sequences, and the sequences were amplified
by the following primers: 5′-CGCCTCGAGCCCAATA
TATGTTAATCTCTTACC-3′ (forward) and 5′-GCGCG
CGTCGACTTTTTAATAAATTTTTACTTGCTA-3′ (re-
verse). The 3′untranslated regions (3′-UTRs) of E2F5 con-
taining an intact miR-181a recognition sequence were
amplified by PCR from genomic DNA, and the PCR prod-
uct was subcloned into a pGL3-control vector (Promega,
Madison, WI) immediately downstream of the luciferase
gene. The primers used were 5′-ATTCTAGATGGGACT
GTTATCTACCT-3′ (forward) and 5′-ACTCTAGAGAT
CCTCGTTTACATCCTTCA-3′ (reverse). A pGL3 con-
struct containing the E2F5 3′-UTR with point muta-
tions in the seed sequence was amplified from the wild
vector. The primers used were 5′-CATATGATTCTGT
AGTAGACCGACAATCAGTGTATG-3′ (forward) and
5′-CATACACTGATTGTCGGTCTACTACAGAATCA
TATG-3′ (reverse). MiR-181a inhibitor, siE2F5 and their
negative controls (NC) were purchased from Invitrogen.
Sequences were as follows: miR-181a inhibitor: ACUCAC
CGACAGCGUUGAAUGUU. siE2F5: sense: 5′-GAGGU
ACCCAUUCCAGAAATT-3′, antisense: 5′-UUUCUGG
AAUGGGUACCUCTT-3′. Ad-HBV adenovirus and its
control Ad-GFP adenovirus were constructed by our
laboratory as following steps: HBV 1.3 fold genome
was ligated into shuttle vector pAdTrack-TO4, then
pAdTrack-TO4-HBV1.3 was linearized by PmeI and
transfected into BJ5183 cells containing pAd-Easy1 to
form a recombinant plasmid. After that the confirmed
recombinant plasmid was linearized by PacI restriction
endonuclease and transfected into HEK-293 cells to
generate recombinant adenoviruses [14].
Stable cell generation
SMMC-7721 cells were transfected with pTARGET-miR-
181a or pTARGET and selected with G418 (1000ug/ml).
Stable cell line p-miR-181a, which could stable express
miR-181a, was established.
Cell proliferation assay
SMMC-7721 cells were trypsinized and seeded into 96-
well culture plates 24 h after transfection with a density
of 7000 cells/well. The cells were harvested at different
time points (24, 48, 72, and 96 h) for growth assay using
the MTS kit (cellTiter96AQ, Promega, USA) following
the manufacturer’s protocol and the absorption was
read at 490 nm.
Colony formation assay
Twenty-four hours after transfection, cells were trypsi-
nized and seeded into 6-well plates with a density of 2000
per well. When the cells grew to visible colonies, the
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paraformaldehyde for 20 min. Next, fixed colonies were
washed again with PBS, and stained with crystal violet for
20 min. Finally, the crystal violet dye was washed with
PBS. The number of colonies was counted under a
microscope.
Luciferase reporter assay
For the luciferase reporter assay, cells were cotransfected
with 300 ng of pGL3-E2F5-WT or pGL3-E2F5-Mut con-
structs and 500 ng pTARGET-miR-181a or negative
control. Each sample was cotransfected with 50 ng of
pRL-TK plasmid expressing renilla luciferase (Promega,
Madison, WI). Cells were collected 48 h after transfection
and analyzed using the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI). Relative luciferase activity
was normalized to renilla luciferase activity. Transfections
were done in duplicate and repeated at least 3 times in
independent experiments.
Reverse-transcription reaction and quantitative real-time
PCR
Total RNAs were extracted with TRIzol reagent (Invi-
trogen, Carlsbad, CA). To analyze miR-181a expression,
miRNA cDNA Kit (CWBIO, China) and miRNA Real-
Time PCR Assay Kit (CWBIO, China) were used. And the
miRNA specific forward primer was 5′-AACATTCAAC
GCTGTCGGTGAGT-3′ and a universal reverse primer
was provided by miRNA Real-Time PCR Assay kit. U6
was used as a miRNA internal control, the primers for U6
were 5′-AGAGCCTGTGGTGTCCG-3′ (forward) and 5′-
CATCTTCAAAGCACTTCCCT-3′ (reverse). To measure
messenger RNA (mRNA) level of E2F5, total RNA was
reversely transcribed using the Reverse Transcription
System (Promega, Madison, WI). The primers used were
5′-TCAGGCACCTTCTGGTACACAACT-3′(forward)
and 5′- AGCAGCACATGGATAGGTCCTGAA-3′(re-
verse). β-actin was used as an endogenous control, the
primers for it were 5′-GTGGATCAGCAAGCAGGAGT-
3′ (forward), 5′-TGTGTGGACTTGGGAGAGGA-3′ (re-
verse). All quantitative real-time polymerase chain reac-
tion (qRT-PCR) samples were performed by using SYBR
Green PCR master mix (CWBIO, China). The real-time
PCR reactions were performed in triplicate and included
no-template controls. Relative changes in gene expression
were calculated using the 2-ΔΔCT method [15].
Western blot analysis
The cells were lysed with 1% RIPA Lysis Buffer (Beyotime,
China) 48 h after transfection. The supernatants were
collected, and protein concentration was determined
using the BCA Assay Kit (Beyotime, China). The protein
samples were separated analyzed by 10% SDS-PAGE and
then transferred to a PVDF membrane. The membranewas blocked with 5% milk, followed by an overnight incu-
bation at 4°C with a primary rabbit antibody against hu-
man E2F5 (Bioword, USA). The membrane was washed
three times in TBST and then incubated with a goat anti-
rabbit HRP secondary antibody. Last, the bound antibody
was detected by chemiluminescence with the ECL Detec-
tion Reagent (Millipore, Billerica, MA). The data were
normalized to β-actin.
Tumor growth assay
Female BALB/c nude mice (4-6 weeks old) were pur-
chased from the Laboratory Animal Services Center of
CUHK. Animal handling and experimental procedures
were approved by the Animal Experimental Ethics Com-
mittee of CUHK. A total of 5 × 106 p-miR-181a cells,
were injected subcutaneously (SC) into the dorsal flank
of nude mice. Each group contained 5 mice. Tumor size
was measured every 2 to 3 days. 2 weeks later, mice were
sacrificed and tumors were dissected.
Immunohistochemistry
Paraformaldehyde-fixed, paraffin-embedded tissues of
transplanted tumors were sectioned at 4.5 μm thickness
and analyzed for Ki-67 (Bioword, 1:50 dilution) and E2F5
(Bioword, 1:100 dilution) expression. Visualization was
achieved by using the 3,3′-diaminobenzidine substrate.
Sections stained with PBS only were used as the nega-
tive staining control.
Statistical analysis
Data are expressed as mean standard deviation (SD).
Statistical analysis was performed by using the independ-
ent t-test. P value of less than 0.05 was considered sta-
tistically significant.
Results
HBV up-regulated the expression of miR-181a by
enhancing its promoter activity
Firstly, the expressions of miR-181a in a panel of cell lines
including HepG2, HepG2.2.15 (a HBV stably transfected
cell lines constitutively producing HBV) and HepG2 cells
infected with recombinant adenoviruses expressing HBV
(Ad-HBV) or GFP (Ad-GFP) were analyzed, and we found
that miR-181a expressions were markedly higher in the
HBV-exprssing cells (HepG2.2.15 and Ad-HBV) when
compared to control cells (Figure 1A, B). These results
were consistent with our previous miRNA microarray
data and illustrated that HBV could up-regulate miR-181a
expression. To further investigate the mechanism of up-
regulation miR-181a by HBV, the activity of miR-181a
promoter was compared in HepG2.2.15 and HepG2 cells
by using luciferase reporter assay. The results showed that
HBV replication enhanced the promoter activity of miR-
181a (P = 0.0084) (Figure 1C). Consistently, the promoter
Figure 1 HBV up-regulated the expression of miR-181a by increasing its promoter activity. (A) Relative expression of miR-181a in HepG2
and HepG2.2.15. (B) Relative expression of miR-181a in Ad-HBV or Ad-GFP infected HepG2 cells. miRNA abundance was normalized to U6 RNA.
(C) Dual luciferase reporter analysis was performed to analyze miR-181a promoter activity in HepG2.2.15 and HepG2 cells. (D) miR-181a promoter
activity in HepG2 cells with Ad-GFP or Ad-HBV infection. *P < 0.05, **P<0.01.
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cells compared with Ad-GFP cells (P = 0.0266) (Figure 1D).
These results suggested that HBV could up-regulate
the expression of miR-181a by increasing its promoter
activity.
MiR-181a overexpression induced cell proliferation in
HCC cells
To determine whether miR-181a could affect cell prolifer-
ation, SMMC-7721 cells were transiently transfected with
pTARGET-miR-181a, miR-181a inhibitor or their negative
controls and then cell growth was measured. Compared
with the NC control, the miR-181a level was decreased
nearly 6 times in SMMC-7721 cells transfected with miR-
181a inhibitor (P = 0.0002) (Figure 2A). On the other
hand, transfection with pTARGET-miR-181a increased
miR-181a expression approximately 8 times, comparedwith control (P = 0.0068) (Figure 2A). The inhibition of
miR-181a resulted in a decrease in cell number over a
course of 4 days (P = 0.0108). In contrast, the overexpres-
sion of miR-181a significantly promoted cell proliferation
(P = 0.0124) (Figure 2B). Furthermore, Clone formation
assay was performed in cells stably express miR-181a
(Figure 2C). Overexpression of miR-181a increased the
number of colonies, compared with control (P = 0.0357)
(Figure 2D).
E2F5 was a target gene of miR-181a
To explore the possible mechanisms of growth regulation
by miR-181a, miR-181a targets were analyzed by using
the TargetScan and MiRanda bioinformatics algorithm.
Software analysis revealed that E2F5 might be a poten-
tial target of miR-181a based on putative target se-
quences of the E2F5 3′-UTR (Figure 3A). We further
Figure 2 MiR-181a overexpression induced cell proliferation in HCC cells. (A) SMMC-7721 cells were transfected with pTARGET-miR-181a,
miR-181a inhibitor and their negative controls. 48 h after transfection, expression of miR-181a was measured by qRT-PCR. (B) Effect of miR-181a
on cell proliferation was measured by MTS assay in pTARGET-miR-181a or miR-181a inhibitor transfected SMMC-7721 cells. (C) Relative miR-181a
expression in p-miR-181a which can stably express miR-181a. miRNA abundance was normalized to U6 RNA. (D) Representative pictures of colony
formation assay of p-miR-181a and p-control cells. Colonies were evaluated and values were reported as the ratio. *P < 0.05, **P<0.01.
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termine whether miR-181a could directly target 3′UTR
of E2F5 in cells. The target sequence of E2F5 3′UTR
(E2F5-WT) or mutant sequence (E2F5-Mut) was cloned
into luciferase vector. The results showed that miR-
181a significantly decreased the luciferase activity of the
E2F5 3′-UTR but not mutant sequence in SMMC-7721
cells (P = 0.0014) (Figure 3B).Moreover, overexpression
of miR-181a significantly down-regulated E2F5 expres-
sion at both the mRNA and protein levels in SMMC-
7721 cells (P = 0.0009) (Figure 3C). In contrast, inhib-
ition of miR-181a resulted in an enhancement of E25F5
mRNA and protein levels (Figure 3D). Taken together,
these data strongly suggest that E2F5 was a direct target
of miR-181a.E2F5 was involved in miR-181a inducing promotion of
HCC cells proliferation
To elucidate whether the growth-promoting effect of
miR-181a was mediated by repression of E2F5 in HCC
cells, the effect of E2F5 on cell growth was examined.
First, SMMC-7721 cells were transfected with siRNA
against E2F5 or the negative control and then we exam-
ined cell growth by MTS assay and colony formation
assay (Figure 4A). MTS assay results showed that gene
silencing of E2F5 promoted cell proliferation of SMMC-
7721 cells (Figure 4A, B). Moreover, the inhibitory effect
of miR-181a inhibitor on cell growth was reversed when
E2F5 expression was knockdown (Figure 4C). Colony
formation assay showed that E2F5 silencing significantly
increased the number of colonies (Figure 4D), similar to
Figure 3 E2F5 was a target gene of miR-181a. (A) Schematic
diagram of predicted miR-181a binding site in the E2F5 3′-UTR.
(B) Luciferase reporter assays in SMMC-7721 cells, with cotransfection
of wt or mut E2F5 3′-UTR and miRNA as indicated. (C) E2F5 mRNA and
protein expression levels in SMMC-7721 cells transfected with
pTARGET-miR-181a or its respective control. (D) E2F5 mRNA and
protein expression levels in SMMC-7721 cells transfected with
miR-181a inhibitor or its negative control. β-actin was used as an
internal quantitative control. *P < 0.05, **P<0.01.
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ings indicated that E2F5 was a functionally important
target of miR-181a which was involved in the prolifera-
tion of HCC cells.HBV down-regulated the expression of E2F5
The above results prompted us to examine whether
HBV could regulate the expression of E2F5. Therefore,
the expression levels of E2F5 were measured in HepG2
cells infected by Ad-HBV or Ad-GFP. E2F5 was down-
regulated in Ad-HBV infected cells in comparison with
the Ad-GFP control group (P = 0.0049) (Figure 5A). The
result demonstrated that HBV was inversely correlated
with E2F5 level.
It has been reported that the growth-promoting effect of
HBV plays an important role in the progression of HBV-
related HCC [16,17]. In this study, HBV was proved to
promote cell growth of hepatoma by MTS (P = 0.0045)
(Figure 5B). To investigate whether HBV promoted cell
growth through regulating miR-181a expression, miR-
181a inhibitor was transfected into HepG2.2.15 cells
and then cell growth was analyzed. The results revealed
that miR-181a inhibited HepG2.2.15 cells resulted in a
decrease of cell viability (P = 0.0169) (Figure 5C). Further-
more, inhibition of miR-181a also reduced the numbers
and size of HepG2.2.15 cells colonies as determined by
colony formation assay (P = 0.0289) (Figure 5D). Our
studies found a new pathway that HBV promoted cells
proliferation, by up-regulating miR-181a expression and
down-regulating E2F5 expression.
MiR-181a promoted tumor growth of SMMC-7721 cells in
nude mice
P-miR-181a or p-control cells were SC injected into the
dorsal flank of nude mice. At 2 weeks after inoculation,
those mice injected with p-miR-181a cells carried larger
burdens (Figure 6A, B). As early as 9 days postimplanta-
tion, the growth of tumor between two groups became
statistically significant. Notably, the average tumor volume
of the p-miR-181a group was markedly larger than that of
control group (P = 0.0006) (Figure 6C).
For a better understanding of the molecular mechanism
of miR-181a on tumorigenesis in vivo, the expression of
Ki-67 and E2F5 were examined in tumor tissues by using
immunohistochemical analysis. The results showed the
staining intensity and the number of Ki-67 positive tumor
cells were increased in p-miR-181a treated group when
compared with control (Figure 6D). The E2F5 positively
stained cells was marked decreased in p-miR-181a treated
group, compared with control (Figure 6D). These results
strongly suggested that miR-181a promoted tumorigenesis
of hepatoma cells in vivo by regulating E2F5 expression.
Discussion
HCC develops through a multistep carcinogenic process,
affecting several tumorigenic-related genes by genetic or
epigeneticchanges [18] and HBV is widely accepted to
be a main cause of HCC. In recent years, miRNAs have
been reported frequently to be involved in many biological
Figure 4 E2F5 was involved in miR-181a inducing promotion of HCC cells proliferation. (A) Western blot was performed to analyze E2F5
expression in siE2F5 transfected SMMC-7721 cells. β-actin was used as an internal quantitative control. (B) Effect of siE2F5 on cell proliferation was
measured by MTS assay. (C) SMMC-7721 cells were transfected with NC, miR-181a inhibitor or miR-181a inhibitor and siE2F5, and then MTS assay
was performed. (D) Representative pictures of colony formation assay of siE2F5 transfected cells. Colonies were evaluated and values were
reported as the ratio between siE2F5 transfected cells and NC transfected cells. *P < 0.05.
Figure 5 HBV down-regulated the expression of E2F5. (A) Relative E2F5 mRNA and protein levels in Ad-GFP or Ad-HBV infected HepG2 cells.
(B) Effect of HBV on cell proliferation was measured by MTS assay in HepG2 cells infected with Ad-HBV. (C) HepG2.2.15 cells were transfected with NC or
miR-181a inhibitor, and then MTS assay was performed. (D) Representative pictures of colony formation assay of miR-181a inhibitor transfected HepG2.2.15
cells. Colonies were evaluated and values were reported as the ratio between miR-181a inhibitor transfected cells and NC transfected cells. **P<0.01.
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Figure 6 MiR-181a promoted tumor growth of SMMC-7721 cells in nude mice. (A) P-miR-181a cells produced larger tumors than control
cells at 14 days after implantation. (B) Representative picture of tumors formed. (C) Growth curve of tumor volumes. Each piece of data represented
the mean ± SD of 5 mice. (D) Ki-67 and E2F5 stained sections of transplanted tumors. *P < 0.05, **P < 0.01.
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reported that several miRNAs were up-regulated in
HepG2.2.15 cells, including miR-181a [13]. Is there any
relationship among HCC, HBV and miR-181a?
Our study firstly showed that up-regulation of miR-181a
in HBV-related HCC cell lines and HBV could induce
miR-181a expression by enhancing its promoter activity. It
is therefore possible that miR-181a might contribute to
the carcinogenesis of HBV-related HCC. Various studies
have shown that the dysregulated of miR-181a was associ-
ated with a variety of human cancers and participates in
the occurrence of multiple human cancers. For example,
Zhu et al. reported that miR-181a improves proliferation
and invasion and suppresses apoptosis of osteosarcoma
cell [20]. However, whether miR-181a plays a role in the
development of HCC has not been addressed. The main
topic of this study is the target gene(s) of miR-181a
and the influence of the up-regulation miR-181a by
HBV on HCC.
Numerous studies show that miR-181a could promote
various cancer cell growths, such as gastric cancer [11],
osteosarcoma [20]. Can miR-181a promote the growth
of hepatoma cells? Our study pointed out that miR-181a
could improve hepatoma cell proliferation in vitro and
tumor growth in vivo. These results suggested that miR-
181a acted as an oncogene in HCC.
The E2F5 protein, a transcription factor, is a key regu-
lator of the cell growth [21]. We firstly identified E2F5as a direct target gene of miR-181a. Silence E2F5 could
improve cell proliferation and rescued the suppressive
effect mediated by miR-181a inhibitor. MiRNA usually
affect several target genes, thus other genes besides E2F5
could also be affected by miR-181a and contributing to
the increase of cell proliferation. For example, the ATM,
TGFBRAP1, and CCNT2 genes could also be the putative
targets of miR-181a and worthy to be investigated.
It has been reported that HBV plays an important role
in promoting cell growth [16,17]. Our study demonstrated
that HBV could promote hepatoma cell proliferation by
down-regulating E2F5 expression. MiR-181a inhibitor
could suppress the growth of HepG2.2.15 cells. All these
findings suggest that HBV promotes cell growth by up-
regulating miR-181a expression and down-regulating
E2F5 expression. Our study found a novel mechanism
for the growth- promoting effect of HBV.
However, further research is still needed to provide a
better understanding of the function and mechanism of
miR-181a in HCC, such as the effect of miR-181a on in-
vasion, migration, metastasis, apoptosis in HCC cells.
Moreover, those results are needed further examined in
HCC samples. In this study, we also examined the effect
of E2F5 on cell cycle progression, but no difference was
observed between siE2F5 transfected cells and its nega-
tive control (data not shown). Qin et al. have reported
that overexpression of E2F5/p130, but not E2F5 alone,
can inhibit E2F-induced cell cycle entry [22]. So E2F5
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The mechanism of the effect of E2F5 and miR-181a on
cell proliferation needs further study. Also, whether
HBV enhanced the activity of miR-181a promoter
through affecting a certain transcription factor is worthy
to investigate.
Conclusions
The key findings of the current study were that miR-
181a could promote cell proliferation in vitro and tumor
formation in vivo by targeting E2F5. HBV could negatively
regulate miR-181a and E2F5 expression. The inhibition of
miR-181a could suppress the growth-promoting effect of
HBV. These data indicated that miR-181a played an essen-
tial role in the regulation of HCC cell proliferation and
may function as an onco-miRNA in HBV-related HCC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CZ and YL conducted the experiments and prepared the manuscript, under
the supervision of HT, who also designed the study. AH gave technical
advice, YC, JJ and JZ contributed with the acquisition of data and also
provided clinical advice during manuscript preparation. YS and SW revised
the final text. All authors read and approved the final manuscript.
Acknowledgments
This work were supported by The Major National S&T program
(2013ZX10002002, ALH), Major project of Chongqing Science & Technology
Commission (cstc2013jcyjC10002, ALH), and Natural Science Foundation
Project of CQ CSTC (2010BB5359).
Author details
1Second Affiliated Hospital, Chongqing Medical University, Chongqing
400016, China. 2Key Laboratory of Molecular Biology on Infectious Diseases,
Ministry of Education, Chongqing Medical University, Chongqing 400016,
China. 3Department of Forensic Medicine, Chongqing Medical University,
Chongqing 400016, China. 4Infection Department of the First Affiliated
Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu
610041, China.
Received: 24 September 2013 Accepted: 11 February 2014
Published: 17 February 2014
References
1. McGlynn KA, London WT: The global epidemiology of hepatocellular
carcinoma: present and future. Clin Liver Dis 2011, 15:223–243.
2. Yuen MF, Hou JL, Chutaputti A: Hepatocellular carcinoma in the Asia
pacific region. J Gastroenterol Hepatol 2009, 24:346–353.
3. Kew MC: Epidemiology of chronic hepatitis B virus infection,
hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular
carcinoma. Pathol Biol (Paris) 2010, 58:273–277.
4. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu HL: Genomic
analysis reveals RhoC as a potential marker in hepatocellular carcinoma
with poor prognosis. Br J Cancer 2004, 90:2349–2355.
5. Blum HE, Spangenberg HC: Hepatocellular carcinoma: an update. Arch Iran
Med 2007, 10:361–371.
6. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
7. Gaal Z, Olah E: MicroRNA-s and their role in malignant hematologic
diseases. Orv Hetil 2012, 153:2051–2059.
8. Lin S, Pan L, Guo S, Wu J, Jin L, Wang JC, Wang S: Prognostic role of
microRNA-181a/b in hematological malignancies: a meta-analysis.
PLoS One 2013, 8(3):e59532.
9. Baer C, Claus R, Plass C: Genome-wide epigenetic regulation of miRNAs in
cancer. Cancer Res 2013, 73:473–477.10. Neel JC, Lebrun JJ: Activin and TGFbeta regulate expression of the
microRNA-181 family to promote cell migration and invasion in breast
cancer cells. Cell Signal 2013, 25:1556–1566.
11. Zhang X, Nie Y, Du Y, Cao J, Shen B, Li Y: MicroRNA-181a promotes gastric
cancer by negatively regulating tumor suppressor KLF6. Tumor Biol 2012,
33:1589–1597.
12. Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, Cheng HW: miR-181 as a
putative biomarker for lymph-node metastasis of oral squamous cell
carcinoma. J Oral Pathol Med 2011, 40:397–404.
13. Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL: Hepatitis B virus
and hepatocelluar carcinoma at the mRNA level. Word J Gastroenterol
2011, 17:3353–3358.
14. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH,
Haydon RC, Kinzier KW, Vogeistein B, He TC: A protocol for rapid
generation of recombinant adenoviruses using the AdEasy system.
Nat Protoc 2007, 2:1236–1247.
15. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods 2001,
25:402–408.
16. Bai Q, An J, Wu X, You H, Ma H, Liu T, Gao N, Jia J: HBV promotes the
proliferation of hepatic stellate cells via the PDGF-B/PDGFR-β signaling
pathway in vitro. Int J Mol Med 2012, 30:1443–1450.
17. Guo GH, Tan DM, Zhu PA, Liu F: Hepatitis B virus X protein promotes
proliferation and up-regulates TGF-beta1 and CTGF in human hepatic
stellate cell line, LX-2. Hepatobiliary Pancreat Dis Int 2009, 8:59–64.
18. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ:
MicroRNA-18a prevents estrogen receptor-alpha expression, promoting
proliferation of hepatocellular carcinoma cells. Gastroenterology 2009,
136:683–693.
19. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for
microRNA genomics. Nucleic Acids Res 2008, 36:D154–D158.
20. Zhu JW, Liu F, Liu XC, Bai EZ, Li S, Li C: MicroRNA 181a improves
proliferation and invasion, suppresses apoptosis of osteosarcoma cell.
Tumor Biol 2013, 38:401–407.
21. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M:
Modulation of hepatitis B virus replication and hepatocyte
differentiation by MicroRNA-1. Hepatology 2011, 53:1476–1485.
22. Chen Q, Liang D, Overbeek PA: Overexpression of E2F5/p130, but not
E2F5 alone, can inhibit E2F-induced cell cycle entry in transgenic mice.
Mol Vis 2008, 14:602–614.
doi:10.1186/1471-2407-14-97
Cite this article as: Zou et al.: Up-regulated MicroRNA-181a induces
carcinogenesis in Hepatitis B virus-related hepatocellular carcinoma by
targeting E2F5. BMC Cancer 2014 14:97.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
